Skip to main content
. Author manuscript; available in PMC: 2007 Nov 5.
Published in final edited form as: Brain Behav Immun. 2007 Feb 9;21(5):581–591. doi: 10.1016/j.bbi.2006.12.003

Figure 6. The effect of the CXCR4 antagonist, AMD3100, on ddC-induced neuropathic pain.

Figure 6

After the induction of neuropathic pain using ddC, AMD3100 was administered and bilateral pain behavior was assessed using the Von-Frey filament test. Behavior was tested at 1, 4 and 24 hours after the administration of AMD3100 (5mg/kg) on post-injection day (PID) -7 and PID14. Following a single injection of ddC, the bilateral paw withdrawal threshold required to elicit a response was significantly reduced at post-injection PID 6 and PID13 compared to vehicle-treated rats (n=6;*p<0.001). Following administration of AMD3100 on PID7 and again at PID14, bilateral paw withdrawal thresholds increased to pre-ddC levels and attenuation of nociceptive behavior lasted for at least 4 hours. Twenty-four hours after AMD3100 treatment, paw withdrawal threshold levels did not differ from PID6 or PID13.